A UK Biobank cohort study of adults with hip (n=41,737) or knee pain (n=81,958) found that among patients with knee

Brand name: Lifyorli Generic name: relacorilant Manufacturer: Corcept Therapeutics Inc. Approval date: March 25, 2026 FDA approved Lifyorli (relacorilant), an

Pfizer and Valneva announced positive topline results from the phase 3 VALOR trial of their investigational Lyme disease vaccine candidate,

A meta-analysis found no evidence that hormonal contraception increases the prevalence of idiopathic intracranial hypertension (IIH). Investigators pooled data from